Fig. 3From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trialFactors associated with PFS of mCRC patients as identified by stratified analysis. LDH lactate dehydrogenase, ULN upper limit of normal, HR hazard ratio, 95% CI 95% confidence intervalBack to article page